Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biospecifics Tech Cp (NQ: BSTC )

88.53 USD UNCHANGED
Last Price Updated: 4:21 PM EST, Dec 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Biospecifics Tech Cp

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Relative Strength Alert For Biospecifics Technologies
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
BRIEF-BioSpecifics Technologies reports Q2 earnings per share $0.36
* BioSpecifics Technologies Corp reports second quarter 2017 financial results 
Tags companyNews
From Reuters: Company News
BioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
PXSG's Underlying Holdings Could Mean 13% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BioSpecifics Technologies Corp. to Present at the Jefferies 2017 Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Can This Biotech Stock With 645% EPS Growth Launch New Breakout?
Innoviva shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Tags IBD Data Stories
From Investor's Business Daily
Pharma Stock With Triple-Digit Growth Forming Blotchy Base
A Relative Strength Rating upgrade for Ionis Pharmaceuticals shows improving technical performance. Will it continue? 
Tags IBD Data Stories
From Investor's Business Daily
Biotech Breakout Ahead? Incyte Rising On Success With Merk, Bristol-Myers
A Relative Strength Rating upgrade for Incyte shows improving technical performance. 
Tags IBD Data Stories
From Investor's Business Daily
Recovering Biotech Stock Enters Buy Zone; Earns Rating Upgrade
Regeneron Pharmaceutical saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96. 
Tags IBD Data Stories
From Investor's Business Daily
How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial
Alnylam stock rocketed to a 19-month high Monday after a Phase 3 trial from rival Ionis de-risked a key Alnylam drug while indicating serious safety questions for Ionis' drug. 
Tags Technology
From Investor's Business Daily
BRIEF-Biospecifics Technologies reports Q1 earnings per share $0.46
* Biospecifics Technologies Corp. reports first quarter 2017 financial results 
Tags companyNews
From Reuters: Company News
BioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Small Cap Best And Worst - Thursday, May 4
The average small cap score is 50.03. The score has averaged 50.47 over the past four weeks. 
Tags Healthcare Financial Consumer Goods
From Blogs - TalkMarkets
BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Small Cap Best And Worst Stocks - Thursday, April 6
The average small cap score is 52.76 and the average score over the past four weeks is 53.08. 
Tags Stocks / Equities
From Blogs - TalkMarkets
BioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
BRIEF-Biospecifics Technologies Q4 earnings per share $0.40
* Biospecifics Technologies Corp reports fourth quarter and full year 2016 financial results 
Tags companyNews
From Reuters: Company News
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2016 Financial Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
Top Biotech May 'Unveil' Breakthrough Treatment — And Breakout Move
Leading biotech stock Celgene (CELG) is within striking distance of a breakout after reporting encouraging results in Unveil, "the first prospective, randomized, controlled study to — evaluate the... 
Tags IBD Stock Analysis
From Investor's Business Daily
BioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
From Marketwired News Releases
BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
BRIEF-Biospecifics Technologies reports Q3 earnings per share $0.42
* Biospecifics Technologies Corp - total revenue for Q3 ended September 30, 2016 was $6.9 million, compared to $6.3 million 
Tags companyNews
From Reuters: Company News
BioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
BioSpecifics Technologies Corp. to Present at Stifel 2016 Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
BioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
18 Stocks Which Rallied Four Days, Then Sold Off Yesterday
The following stocks posted four-day rallies spanning the trading days from September 23 to September 28 and then saw profit ... 
Tags Trading Ideas HQCL Markets
From Benzinga
Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q3 Expectations
Following the market opening Tuesday, the Dow traded up 0.44 percent to 18,200.26 while the NASDAQ climbed 0.39 percent ... 
Tags BSTC TBRA Global
From Benzinga
25 Stocks Which Rallied Three Days
The list of below stocks is notable as the shares have rallied for three days in a row spanning the trading days from September 13 ... 
Tags GNC CEMP EDU
From Benzinga
BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.